Side Effects of everolimus: A Synthesis of Findings from 24 Studies

  1. Home
  2. Side Effects of everolimus
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of everolimus: A Synthesis of Findings from 24 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of everolimus: A Synthesis of Findings from 24 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Everolimus is an immunosuppressant agent used in organ transplantation and cancer therapy. 10 It has shown beneficial effects in breast cancer, renal cancer, and neuroendocrine tumors. 8 , 10 However, the treatment is not without side effects. Everolimus has been shown to be safe as a second-/third-line therapy in pediatric autoimmune hepatitis. 2 Everolimus treatment significantly increased circulating regulatory T cell levels after liver transplantation, suggesting potential advantages over standard tacrolimus-based immunosuppressive therapy. 11 While everolimus is generally well-tolerated in patients with tuberous sclerosis complex, there is a potential for rare side effects not observed in previous clinical trials. 15 Everolimus is an mTOR inhibitor that works by inhibiting the mTOR pathway, a crucial pathway controlling cell growth, differentiation, and metabolism. 6 , 23

Reasons for Side Effects

The side effects of everolimus are caused by the inhibition of the mTOR pathway. 6 , 23 Inhibiting this pathway can suppress cell growth, reducing the activity of immune cells. This can lead to side effects such as infections, anemia, and thrombocytopenia. 24 , 20 Everolimus can also affect cell metabolism, causing side effects like hyperlipidemia, hyperglycemia, and stomatitis. 22 , 15

Common Side Effects

Infections

Everolimus can increase the risk of infections due to its immunosuppressive properties. 4 , 7 , 21

Anemia

Anemia can occur as a side effect of everolimus. 4 , 24

Thrombocytopenia

Thrombocytopenia can occur as a side effect of everolimus. 4 , 24

Hyperlipidemia

Hyperlipidemia can occur as a side effect of everolimus. 4 , 15

Hyperglycemia

Hyperglycemia can occur as a side effect of everolimus. 21 , 15

Stomatitis

Stomatitis can occur as a side effect of everolimus. 22 , 15

Interstitial Lung Disease

Interstitial lung disease can occur as a side effect of everolimus. 24

Skin Side Effects

Skin side effects like papulopustular rash can occur as a side effect of everolimus. 22

Renal Microangiopathy

Renal microangiopathy may occur in patients receiving lenvatinib and everolimus in combination. 1

Side Effects Management

Infections

To reduce the risk of infections, it is crucial to maintain good hygiene practices such as hand washing and gargling. 4 Early detection and treatment of infections are also critical. 7

Anemia

If anemia symptoms arise, consult a physician. Iron supplements or other treatment medications may be prescribed as needed. 4 , 24

Thrombocytopenia

If thrombocytopenia symptoms occur, seek medical advice. Blood transfusions or other treatment options may be necessary. 4 , 24

Hyperlipidemia

Consult a physician if you experience hyperlipidemia symptoms. Dietary adjustments or medication may be recommended. 4 , 15

Hyperglycemia

If you experience hyperglycemia symptoms, consult a physician. Dietary changes or medication may be prescribed. 21 , 15

Stomatitis

Consult a physician if stomatitis symptoms arise. Mouthwashes or pain relievers may be prescribed as needed. 22 , 15

Interstitial Lung Disease

Consult a physician if you experience interstitial lung disease symptoms. Treatment options may include reducing or discontinuing everolimus dosage. 24

Skin Side Effects

Consult a physician if you experience skin side effects. Topical steroids or other treatment medications may be prescribed as needed. 22

Renal Microangiopathy

Consult a physician if you experience renal microangiopathy symptoms. Treatment options may include reducing or discontinuing lenvatinib dosage. 1

Comparison Across Studies

Similarities

Numerous studies have reported on the effectiveness and side effects of everolimus. 2 , 8 , 10 , 11 , 13 , 14 , 4 , 7 , 15 , 6 , 23 , 17 , 12 , 21 , 19 , 3 , 22 , 1 , 18 , 5

Differences

The intended use, target diseases, dosage, and side effects of everolimus can vary between studies. 2 , 8 , 10 , 11 , 13 , 14 , 4 , 7 , 15 , 6 , 23 , 17 , 12 , 21 , 19 , 3 , 22 , 1 , 18 , 5

Considerations for Real-Life Application

Everolimus holds promise for treating various diseases, but it carries the risk of side effects. 4 , 7 , 21 , 24 , 15 When considering everolimus use, it is crucial to consult with a physician and thoroughly understand both the risks and benefits before making a decision. 4 , 7 , 21 , 24 , 15

Limitations of Current Research

Current research on the side effects of everolimus is not yet comprehensive. 4 , 7 , 21 , 24 , 15 Further research is needed. 4 , 7 , 21 , 24 , 15

Future Research Directions

Further research is necessary to investigate the side effects of everolimus in greater detail. 4 , 7 , 21 , 24 , 15 Research focused on understanding how everolimus impacts the treatment of various diseases is particularly important. 4 , 7 , 21 , 24 , 15

Conclusion

Everolimus shows promise as a treatment option for various diseases, but it comes with the potential for side effects. 4 , 7 , 21 , 24 , 15 When considering everolimus, consult with a physician to fully understand the risks and benefits before making a decision. 4 , 7 , 21 , 24 , 15

Keywords
Benefit Keywords
Thyroid cancer treatment
1
AIH treatment
2
Improved graft survival
Improved patient survival
Reduced immunosuppression side effects
3
HCC recurrence reduction
Survival improvement
4
Autoimmune Disease Treatment
Transplantation
5
Cancer treatment
Lung fibrosis treatment
Transplantation
6
immuno tolerance
kidney transplantation
7
Tumor regression
8
Breast cancer treatment
9
Neuroendocrine tumor treatment
10
Increased Tregs levels
Reduced immunosuppressive regimen
11
Decreases AML size
Well-tolerated
12
Life extension
13
ADPKD treatment
Reduced off-target effects
14
TSC treatment
Well tolerated
15
NEN management
16
Decreased side effects
Enhanced therapeutic efficacy
17
Bioequivalence
NTI drug development
Sample size reduction
18
Uterine LAM treatment
19
mRCC treatment
20
Improved long-term outcomes
Reduced side effects
Superior graft function
21
Targeted therapy
22
Treat cancer
Treat transplantation
23
Prolonged progression-free survival
24
Risk Keywords
Renal TMA
1
Immunosuppression side effects
3
Abnormal healing
Acne
Anemia
Depression
Diarrhea
Dyslipidemia
Edema
Headache/migraine
Hypercholesterolemia
Incisional hernia
Infection
Leukopenia
Mouth ulceration
Proteinuria
Pruritis
Pyrexia
Rash
Thrombocytopenia
4
Side Effects
Toxicity
5
Profibrotic side effects
6
graft loss
rejection episodes
side effects
7
Side effects
9
Complex regional pain syndrome
10
Side effects
12
Drug side effects
13
Mild side effects
15
Side effects
19
Diabetes
Infections
Rejection
21
Papulopustular rash
Skin toxicities
22
Adverse reactions
23
Infections
Interstitial lung disease
Stomatitis
Thrombocytopenia
24
Literature analysis of 24 papers
Positive Content
24
Neutral Content
0
Negative Content
0
Article Type
2
1
1
3
23
2.

Everolimus is Safe as a Second-/Third-Line Therapy in Pediatric Autoimmune Hepatitis.

Author: JannoneGiulia, ScheersIsabelle, SmetsFrançoise, StephenneXavier, M SokalEtienne

AIH treatment

This study shares the authors' experience about everolimus as a second-/third-line therapy in pediatric AIH.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

3.

Immunosuppressive Drugs in Liver Transplant: An Insight.

Author: PanackelCharles, MathewJoe F, Fawas NMohamed, JacobMathew

Improved graft survival
Improved patient survival
Reduced immunosuppression side effects
Immunosuppression side effects

Liver transplantation (LT) requires immunosuppression to prevent rejection, but the side effects of these agents pose challenges. This review discusses the current status of personalized immunosuppression, aiming to optimize efficacy while minimizing side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

mTORi-based immunosuppression reduces HCC recurrence at the expense of increased adverse side effects: A systematic review and meta-analysis.

Author: ZhangGongming, DuanBinwei, LiGuangming

HCC recurrence reduction
Survival improvement
Abnormal healing
Acne
Anemia
Depression
Diarrhea
Dyslipidemia
Edema
Headache/migraine
Hypercholesterolemia
Incisional hernia
Infection
Leukopenia
Mouth ulceration
Proteinuria
Pruritis
Pyrexia
Rash
Thrombocytopenia

This systematic review and meta-analysis compared the efficacy and safety of mammalian target of rapamycin inhibitors (mTORi) versus calcineurin inhibitors (CNI) in hepatocellular carcinoma (HCC) patients after liver transplantation (LT). The analysis found that mTORi significantly reduced tumor recurrence and mortality but increased the incidence of several adverse events compared to CNI.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Patient with Lobular Carcinoma of the Breast and Activating AKT1 E17K Variant.

Author: TrivediHarsha, HamdaniOmar, ThomasBrittani, RichardJames, ShahKunal, RaskinaKira, ZhangLiang, MadiganAudrey, FoxMarshall, WanderSeth, FrigaultMatthew J, AlexanderBrian, SrkalovicGordan

Tumor regression

Precision medicine tools, such as molecular tumor boards and real-world data sets, can provide more treatment options for patients with metastatic breast cancer.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

9.

[Combination of exemestane and everolimus may produce toxic side effects: a new treatment option for metastatic hormone-sensitive breast cancer].

Author: VincentJeroen, de BoerMaaike, LobbezooDorien J A, SmeetsRuud E H, Tjan-HeijnenVivianne C G

Breast cancer treatment
Side effects

The combination of exemestane and everolimus is a new treatment option for metastatic hormone-sensitive breast cancer. This article discusses the efficacy and common side effects of this treatment, along with recommendations for their management.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : Dutch

10.

Complex regional pain syndrome in a patient with neuroendocrine tumour under treatment with everolimus.

Author: Pérez de Amezaga-TomásLuis, Oliver-NogueraAina, Rodríguez-CamachoJuan Manuel, Fernández-RodríguezTeresa

Neuroendocrine tumor treatment
Complex regional pain syndrome

A 56-year-old man with a neuroendocrine tumor developed complex regional pain syndrome (CRPS) after being treated with everolimus, highlighting a potential side effect of this immunosuppressant.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

11.

Influence of everolimus-based treatment on circulating regulatory T cells after liver transplantation: Comparative study with tacrolimus-based therapy.

Author: BarjonClément, DahlqvistGéraldine, GhazalKhaldoun, SalibaFaouzi, DurandFrançois, DuvouxChristophe, AoudjehaneLynda, ContiFilomena

Increased Tregs levels
Reduced immunosuppressive regimen

Everolimus, an mTOR inhibitor, may be beneficial for liver transplant patients, as it has been shown to promote natural regulatory T cells (Tregs), which are crucial for achieving tolerance and reducing immunosuppressive regimen needs.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

14.

In vitro delivery of mTOR inhibitors by kidney-targeted micelles for autosomal dominant polycystic kidney disease.

Author: CoxAlysia, TungMadelynn, LiHui, HallowsKenneth R, ChungEun Ji

ADPKD treatment
Reduced off-target effects

Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic condition that can lead to kidney failure. The mTOR pathway is implicated in the growth of cysts, and inhibiting it with drugs like rapamycin can help, but these drugs have side effects. This study investigated the use of targeted drug delivery carriers, specifically peptide amphiphile micelles (PAMs), to deliver mTOR inhibitors directly to kidney cells, potentially minimizing side effects and improving efficacy in treating ADPKD.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

15.

Diabetes in Individuals With Tuberous Sclerosis Complex Treated With mTOR Inhibitors.

Author: AgricolaKaren, StiresGabrielle, KruegerDarcy A, CapalJamie K, FranzDavid N, RitterDavid M

TSC treatment
Well tolerated
Mild side effects

Everolimus and sirolimus, mammalian target of rapamycin inhibitors, are effective treatments for various clinical manifestations of tuberous sclerosis complex, including subependymal giant cell astrocytoma and epilepsy. While generally well tolerated with manageable side effects, these medications may also lead to rare adverse effects, requiring close monitoring.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

16.

Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia: a systematic review.

Author: RinzivilloMaria, De FeliceIlaria, MagiLudovica, AnnibaleBruno, PanzutoFrancesco

NEN management

Octreotide long-acting release is a first-line treatment for neuroendocrine neoplasia. This systematic review examined its role in combination with other therapies for NEN management.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

17.

Metronomic combination chemotherapy using everolimus and etoposide for the treatment of non-Hodgkin lymphoma.

Author: WuKe, SunXiao-Qing, WangCai-Qin, GaoTian-Xiao, SunPeng, WangYu, JiangWen-Qi, LiZhi-Ming, HuangJia-Jia

Decreased side effects
Enhanced therapeutic efficacy

A combination of etoposide and everolimus was more effective than etoposide alone in treating Non-Hodgkin lymphoma.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

A Case of Uterine Lymphangioleiomyomatosis Complicated by Tuberous Sclerosis Complex.

Author: YamadaKaori, YamanishiYukio, AratakeJunichi, SasagasakoNanayo, InayamaYoshihide, GouRei, KawamuraAtsuko, YamanishiMegumi, KosakaKenzo

Uterine LAM treatment
Side effects

This case report describes an uncommon presentation of uterine lymphangioleiomyomatosis (LAM) in a patient with tuberous sclerosis complex (TSC). Treatment with everolimus, an mTOR inhibitor, resulted in temporary reduction of uterine tumor size. The case emphasizes the need to consider uterine LAM in patients with TSC presenting with genital bleeding or abdominal pain. mTOR inhibitors may be a treatment option, alongside surgery, for uterine LAM exacerbation.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

20.

New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies.

Author: GrimmMarc-Oliver, LeuchtKatharina, GrünwaldViktor, FollerSusan

mRCC treatment

This review discusses the use of PD-1 immune-checkpoint inhibitors (ICIs) in the treatment of metastatic renal cell carcinoma (mRCC). Nivolumab, a PD-1 ICI, became a standard second-line treatment option in 2015. More recently, PD-1 ICI-based combinations have shown improved efficacy compared to previous standard of care treatments.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

21.

5-Year outcomes of the prospective and randomized CISTCERT study comparing steroid withdrawal to replacement of cyclosporine with everolimus in de novo kidney transplant patients.

Author: PipeleersLissa, AbramowiczDaniel, BroedersNilufer, LemoineAlain, PeetersPatrick, Van LaeckeSteven, WeekersLaurent E, SennesaelJacques, WissingKarl M, GeersCaroline, BosmansJean-Louis

Improved long-term outcomes
Reduced side effects
Superior graft function
Diabetes
Infections
Rejection

This study compares the efficacy and safety of two strategies for reducing treatment-related side effects in kidney transplant recipients: steroid withdrawal and replacement of cyclosporine with everolimus. The study found that both regimens provide excellent long-term survival but differ in graft function and other outcomes, suggesting that each approach may be suitable for different patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

24.

[Management of side effects of everolimus treatment for metastatic renal cell carcinoma].

Author: MikamiKazuya, HongoFumiya, MikiTsuneharu

Prolonged progression-free survival
Infections
Interstitial lung disease
Stomatitis
Thrombocytopenia

Everolimus, a drug used to treat renal cell carcinoma, can cause various side effects, including interstitial lung disease. This review summarizes the known side effects of everolimus and how to manage them.

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : Japanese

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.